- Home
- VINP vs PCRX Comparison
VINP vs PCRX Comparison
Compare VINP & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- PCRX
- Stock Information
- Founded
- VINP 2009
- PCRX 2006
- Country
- VINP Brazil
- PCRX United States
- Employees
- VINP N/A
- PCRX N/A
- Industry
- VINP Investment Managers
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- VINP Finance
- PCRX Health Care
- Exchange
- VINP Nasdaq
- PCRX Nasdaq
- Market Cap
- VINP 593.2M
- PCRX 1.2B
- IPO Year
- VINP 2021
- PCRX 2011
- Fundamental
- Price
- VINP $9.40
- PCRX $22.73
- Analyst Decision
- VINP Strong Buy
- PCRX Buy
- Analyst Count
- VINP 2
- PCRX 8
- Target Price
- VINP $13.25
- PCRX $28.38
- AVG Volume (30 Days)
- VINP 57.7K
- PCRX 492.0K
- Earning Date
- VINP 08-12-2025
- PCRX 07-29-2025
- Dividend Yield
- VINP 6.91%
- PCRX N/A
- EPS Growth
- VINP N/A
- PCRX N/A
- EPS
- VINP 0.38
- PCRX N/A
- Revenue
- VINP $126,696,258.00
- PCRX $702,772,000.00
- Revenue This Year
- VINP $70.28
- PCRX $7.92
- Revenue Next Year
- VINP $14.37
- PCRX $11.02
- P/E Ratio
- VINP $24.69
- PCRX N/A
- Revenue Growth
- VINP 57.51
- PCRX 3.08
- 52 Week Low
- VINP $8.66
- PCRX $11.16
- 52 Week High
- VINP $11.62
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- VINP 43.26
- PCRX 36.58
- Support Level
- VINP $9.20
- PCRX $22.23
- Resistance Level
- VINP $9.94
- PCRX $23.91
- Average True Range (ATR)
- VINP 0.22
- PCRX 0.82
- MACD
- VINP -0.02
- PCRX -0.01
- Stochastic Oscillator
- VINP 27.21
- PCRX 22.03
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.